HKEX: 2500
Poll results of the extraordinary general meeting
View original source (HKEXnews)
Earlier from Venus Medtech (hangzhou), Inc. Class H
- Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
- Court Sides with Cardiovalve in Edwards patent spat
- Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
- Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve